



Announcement Summary

Entity name

CRESO PHARMA LIMITED

Announcement Type

New announcement

Date of this announcement

Thursday July 14, 2022

The +securities to be quoted are:

☒ Other

Total number of +securities to be quoted

ASX +security code	Security description	Number of +securities to be quoted	Issue date
CPH	ORDINARY FULLY PAID	100,000	14/07/2022

Refer to next page for full details of the announcement



Part 1 - Entity and announcement details

1.1 Name of entity

CRESO PHARMA LIMITED

We (the entity named above) apply for +quotation of the following +securities and agree to the matters set out in Appendix 2A of the ASX Listing Rules.

1.2 Registered number type

ABN

Registration number

89609406911

1.3 ASX issuer code

CPH

1.4 The announcement is

☒ New announcement

1.5 Date of this announcement

14/7/2022



Part 2 - Type of Issue

2.1 The +securities to be quoted are:

☒ Other

2.2 The +securities to be quoted are:

☒ Additional +securities in a class that is already quoted on ASX ("existing class")

2.3c Have these +securities been offered under a +disclosure document or +PDS?

☒ No

2.3d Please provide any further information needed to understand the circumstances in which you are applying to have these +securities quoted on ASX, including why the issue of the +securities has not been previously announced to the market in an Appendix 3B

The issue has not been previously announced to the market in an Appendix 3B because the date of the agreement to issue the securities is the same date as the actual date of issue of the securities.

2.4 Any on-sale of the +securities to be quoted within 12 months of their date of issue will comply with the secondary sale provisions in sections 707(3) and 1012C(6) of the Corporations Act by virtue of:

☒ The publication of a +disclosure document or +PDS involving the same class of securities as the +securities to be quoted that meets the requirements of section 708A(11) or 1012DA(11)



Part 3B - number and type of +securities to be quoted (existing class) where issue has not previously been notified to ASX in an Appendix 3B

Additional +securities to be quoted in an existing class

ASX +security code and description

CPH : ORDINARY FULLY PAID

Issue date

14/7/2022

Will the +securities to be quoted rank equally in all respects from their issue date with the existing issued +securities in that class?

☒ Yes

Issue details

Number of +securities to be quoted

100,000

Are the +securities being issued for a cash consideration?

☒ No

Please describe the consideration being provided for the +securities

100,000 shares issued to the nominee of Mr Van Biezen, as part consideration for his services under his Brand Ambassador and Strategic Adviser Agreement with subsidiary, Creso Pharma ImpACTIVE Inc.

Please provide an estimate (in AUD) of the value of the consideration being provided per +security for the +securities to be quoted

3,900.000000

Any other information the entity wishes to provide about the +securities to be quoted

The estimated consideration is arbitrary and was calculated solely for the purpose of this Appendix 2A, based on the closing price of CPH Shares at 13 July 2022.

The purpose(s) for which the entity is issuing the securities

To pay for services rendered

Please provide additional details

Further details are set out in the ASX release dated 14 July 2022.





Part 4 - Issued capital following quotation

Following the quotation of the +securities the subject of this application, the issued capital of the entity will comprise:

(A discrepancy in these figures compared to your own may be due to a matter of timing if there is more than one application for quotation/issuance currently with ASX for processing.)

4.1 Quoted +securities (total number of each +class of +securities quoted on ASX following the +quotation of the +securities subject of this application)

ASX +security code and description	Total number of +securities on issue
CPHOA : OPTION EXPIRING 22-JAN-2023	63,958,997
CPH : ORDINARY FULLY PAID	1,296,492,953
CPHO : OPTION EXPIRING 02-NOV-2024	400,941,788

4.2 Unquoted +securities (total number of each +class of +securities issued but not quoted on ASX)

ASX +security code and description	Total number of +securities on issue
CPHAAN : OPTION EXPIRING 06-SEP-2024 EX \$0.25	10,000,000
CPHAAO : PERFORMANCE RIGHTS	15,000,000
CPHAY : OPTION EXPIRING 02-JUN-2023 EX 17C	27,764,706
CPHAAA : OPTION EXPIRING 02-JUN-2023 EX 20C	8,000,000
CPHAZ : OPTION EXPIRING 02-JUN-2023 EX 25C	4,000,000
CPHAQ : OPTION EXPIRING 15-SEP-2022 EX 80C	300,000
CPHAAB : OPTION EXPIRING 25-JUN-2023 EX 13.86C	5,752,688
CPHAAL : OPTION EXPIRING 01-AUG-2024 EX \$0.18	12,000,000
CPHAS : OPTION EXPIRING 12-FEB-2023 EX 40C	6,847,725
CPHAT : OPTION EXPIRING 12-FEB-2023 EX 35C	2,128,387
CPHAAK : OPTION EXPIRING 01-AUG-2024 EX \$0.15	12,000,000



CPHAAM : OPTION EXPIRING 06-SEP-2024 EX \$0.18	10,000,000
CPHAL : OPTION EXPIRING VARIOUS DATES EX VARIOUS PRICES	200,000
CPHAM : PERFORMANCE RIGHTS	2,399,000
CPHAAC : OPTION EXPIRING 11-JAN-2023 EX \$0.235	8,000,000
CPHAAD : OPTION EXPIRING 11-JAN-2023 EX \$0.27	8,000,000
CPHAAE : OPTION EXPIRING 11-JAN-2023 EX \$0.30	8,000,000
CPHAAF : OPTION EXPIRING 11-JAN-2023 EX \$0.40	2,800,000
CPHAAG : OPTION EXPIRING 23-DEC-2023 EX \$0.20	833,333
CPHAAH : OPTION EXPIRING 23-DEC-2025 EX \$0.039	30,000,000
CPHAU : OPTION EXPIRING 01-MAR-2023 EX 25C	250,000
CPHAAI : OPTION EXPIRING 14-JUL-2024 EX \$0.38	12,000,000
CPHAAP : OPTION EXPIRING 25-OCT-2024 EX \$0.1375	1,000,000



Part 5 - Other Listing Rule requirements

5.1 Are the +securities being issued under an exception in Listing Rule 7.2 and therefore the issue does not need any security holder approval under Listing Rule 7.1?

☒ No

5.2 Has the entity obtained, or is it obtaining, +security holder approval for the issue under listing rule 7.1?

☒ No

5.2b Are any of the +securities being issued without +security holder approval using the entity's 15% placement capacity under listing rule 7.1?

☒ Yes

5.2b.1 How many +securities are being issued without +security holder approval using the entity's 15% placement capacity under listing rule 7.1?

100,000 shares.

5.2c Are any of the +securities being issued without +security holder approval using the entity's additional 10% placement capacity under listing rule 7.1A (if applicable)?

☒ No